Reports Q1 revenue $29.38M, consensus $23.35M. “We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to provide meaningful Phase 2 interim data mid-year,” said Joseph Payne, President & CEO of Arcturus Therapeutics (ARCT). “We are encouraged by the clinical progress of our CF and OTC programs, and given the current market conditions, we made a strategic decision to streamline resources to focus on our mRNA therapeutics pipeline.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Arcturus Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
- Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
- Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
- Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA